117 related articles for article (PubMed ID: 33021743)
1. An evaluation of no-treatment decisions in patients with newly diagnosed acute myeloid leukemia.
Brandwein JM; Hallett D; Karkhaneh M; Zhu N; Liew E; Bolster L; Hamilton M; Patterson J; Taparia M; Wu C; Van Slyke T; Bankar A; Saini L
Am J Hematol; 2021 Jan; 96(1):E17-E20. PubMed ID: 33021743
[No Abstract] [Full Text] [Related]
2. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia.
Kadia T; Kantarjian H; Garcia-Manero G; Borthakur G; Wang X; Patel K; Jabbour E; Brandt M; Daver N; Pemmaraju N; Pierce S; Cortes J; Ravandi F
Br J Haematol; 2015 Aug; 170(4):590-3. PubMed ID: 25716073
[No Abstract] [Full Text] [Related]
4. Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Minetto P; Guolo F; Clavio M; Kunkl A; Colombo N; Carminati E; Fugazza G; Matarese S; Guardo D; Ballerini F; Di Grazia C; Raiola AM; Cagnetta A; Cea M; Miglino M; Lemoli RM; Gobbi M
Br J Haematol; 2019 Feb; 184(3):457-460. PubMed ID: 29359798
[No Abstract] [Full Text] [Related]
5. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
[TBL] [Abstract][Full Text] [Related]
6. Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.
Shadman M; Mawad R; Dean C; Chen TL; Shannon-Dorcy K; Sandhu V; Hendrie PC; Scott BL; Walter RB; Becker PS; Pagel JM; Estey EH
Am J Hematol; 2015 Jun; 90(6):483-6. PubMed ID: 25689471
[TBL] [Abstract][Full Text] [Related]
7. Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.
Ruutu T; Koivunen E; Nousiainen T; Pelliniemi TT; Almqvist A; Anttila P; Jantunen E; Koistinen P; Koponen A; Mikkola M; Oksanen K; Pulli T; Remes K; Sarkkinen R; Silvennoinen R; Timonen T; Vanhatalo S; Elonen E;
Eur J Haematol; 2004 Jan; 72(1):38-44. PubMed ID: 14962261
[TBL] [Abstract][Full Text] [Related]
8. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Estey EH; Kantarjian H; Keating M
Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966
[TBL] [Abstract][Full Text] [Related]
9. Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years.
Österroos A; Eriksson A; Antunovic P; Cammenga J; Deneberg S; Lazarevic V; Lorenz F; Möllgård L; Derolf ÅR; Uggla B; Wennström L; Ölander E; Höglund M; Juliusson G; Lehmann S
Br J Haematol; 2020 Apr; 189(1):e13-e16. PubMed ID: 32103493
[No Abstract] [Full Text] [Related]
10. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
11. Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life.
Huet S; Paubelle E; Lours C; Grange B; Courtois L; Chabane K; Charlot C; Mosnier I; Simonet T; Hayette S; Tigaud I; Thomas X; Salles G; Subtil F; Sujobert P
Blood; 2018 Aug; 132(8):865-867. PubMed ID: 29866812
[No Abstract] [Full Text] [Related]
12. FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
Candoni A; Simeone E; Tiribelli M; Malagola M; Russo D; Fanin R
Am J Hematol; 2009 Oct; 84(10):690-2. PubMed ID: 19731308
[No Abstract] [Full Text] [Related]
13. Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
Pirrotta MT; Bocchia M; Bucalossi A; Defina M; Forconi F; Gozzetti A; Lauria F
Acta Haematol; 2007; 118(1):7-9. PubMed ID: 17389781
[No Abstract] [Full Text] [Related]
14. Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
Lambertenghi-Deliliers G; Annaloro C; Cortelezzi A; Cortellaro M; Della Volpe A; Maiolo AT; Mozzana R; Pogliani E; Pozzoli E; Polli EE
Semin Oncol; 1989 Feb; 16(1 Suppl 2):16-20. PubMed ID: 2928806
[No Abstract] [Full Text] [Related]
15. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
16. Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
Jin J; Chen J; Suo S; Qian W; Meng H; Mai W; Tong H; Huang J; Yu W; Wei J; Lou Y
Leuk Lymphoma; 2015 Jun; 56(6):1691-7. PubMed ID: 25257348
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
Kim I; Koh Y; Yoon SS; Park S; Kim BK; Kim DY; Lee JH; Lee KH; Cheong JW; Lee HK; Kim SH; Kim H; Joo YD; Lee SM; Won JH; Park SK; Hong DS; Kim SH; Sohn SK; Kim CS; Park E; Kim MK; Park MR; Lee JH; Min YH;
Am J Hematol; 2013 Jan; 88(1):10-5. PubMed ID: 23077109
[TBL] [Abstract][Full Text] [Related]
18. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F
Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352
[TBL] [Abstract][Full Text] [Related]
19. Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young adults.
Tsui SP; Ip HW; Saw NY; Zhang C; Cheung AK; Ng NK; Man CH; Lam SS; Tang WF; Lin CH; Cheng GH; Au CH; Ma ES; Chan TL; So JC; Ng MH; Cheng KC; Wong KF; Siu LP; Yip SF; Lin SY; Lau JS; Luk TH; Lee HK; Lau CK; Kho B; Sim JP; Kwong YL; Leung SY; Javed A; Leung AY
Blood Cancer J; 2020 Oct; 10(10):104. PubMed ID: 33077814
[No Abstract] [Full Text] [Related]
20. Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
Montillo M; Ricci F; Tedeschi A; Cafro AM; Nosari AM; Nichelatti M; Marbello L; Morra E
Leuk Res; 2009 Aug; 33(8):1072-8. PubMed ID: 19187960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
